HCV Treatment: The current treatment for
hepatitis C, including outcomes, side effects and treatment of various HCV
1233. Rapid virologic response is
common in acute hepatitis C virus (HCV) infection regardless of genotype.
266. Naturally occurring STAT-C resistance
mutations in treatment-naïve HCV infected patients - an international
168. A Randomized,
Double-Blind, Placebo-Controlled Study of PPAR-gamma Agonist Pioglitazone Given
in Combination with Peginterferon and Ribavirin in Patients with Genotype-1
Chronic Hepatitis C.
263. Sustained Virological Response is
Associated with Decrease in Liver Stiffness Using FibroScan in Patients with
HCV Related Cirrhosis.
264. Lower Risk of Hepatocellular Carcinoma
and Improved Survival in patients with HCV Related Cirrhosis with Sustained
267. Decline in Sexual Desire, Function and
Satisfaction in Men During Peginterferon and Ribavirin Therapy for Chronic
520. Sustained virological
response (SVR) to pegylated interferon and ribavirin has no effect on
neurocognition and cerebral metabolite levels in patients with chronic
521. Hepatitis c among HEAVY
ALCOHOL CONSUMERS : Does it require treatment?
1220. Anti-viral therapy in haemodialyzed
HCV patients: efficacy, tolerance and treatment strategy.
1232. Re-infection following
successful treatment for Hepatitis C virus Infection. (updated Nov 3, 2008)
1241. Interferon therapy for
hepatitis C patients curatively treated for hepatocellular carcinoma with
percutaneous therapies. (updated Nov 3, 2008)
1242. Sustained Virological
Response in Patients with Chronic Hepatitis C is Similar Between Whites and
Non-Whites: Evaluation Using Specific Ancestry Alleles Analysis in an Admixed
1252. Determinants of HCV Antiviral
Treatment in a Managed Care Setting.
1253. Assessment of serum HCV RNA
at week 12 post-treatment is as relevant as week 24 to predict SVR in patients
with chronic hepatitis C treated with Pegylated interferon plus ribavirin. (updated Nov 4, 2008)
1261. The Impact Of
A Multi-Disciplinary Support Program On Adherence And The Efficacy Of Hepatitis
C Treatment. (updated Nov 3, 2008)
1266. Education Program (Ep)
Improves The Rate Of Sustained Virologic Response (Svr) To Anti-HCV Therapy:
Multivariate Analysis From A French Network Experience. (updated Nov 3, 2008)
1271. Insulin Resistant Chronic
Hepatitis C (CHC): The Effect of Sustained Virological Response (SVR) on
Insulin Resistance (IR) Status, Insulin Secretion, Lipid Profile and
1290. A retrospective comparative
study of Pegylated interferon and ribavirin for the treatment of chronic
hepatitis C genotype 6 and genotype 1. (updated Nov 3, 2008)
1314. Long-term efficacy of
peginterferon with ribavirin therapy on incidence of hepatocellular carcinoma
in patients with hepatitis C virus-related advanced fibrosis.
1317. Differences in Adherence to
PEG-Interferon and Ribavirin Among Subgroups Perceived
to be At-Risk for Non-Adherence. (updated Nov 4, 2008)
1321. Effectiveness of Hepatitis C
Treatment with Pegylated Interferon and Ribavirin in an Urban Patient
1325. Outcomes of Antiviral Therapy
for Hepatitis C in Day to Day Clinical Practice. (updated
Nov 4, 2008)
1338. Management of Chronic Hepatitis
C Patients with Schizophrenia: Should we treat?
1945. Association of Lipid Profiles with
Hepatitis C Viral Load in Chronic Hepatitis C Patients with Genotype 1 and 2
1257. Adherence and response rate
to anti viral treatment do not seem to be affected by intravenous drug use in
patients with chronic hepatitis C under substitution therapy. (updated Nov 3, 2008)
1286. Specific joint
hepatology–addiction medicine follow-up of hepatitis C treatment for
intravenous drug users (IDU) or ex-IDU improves treatment response. (updated Nov 3, 2008)
1297. Impact of Recent Substance
Use on Antiviral Treatment for Chronic Hepatitis C. (updated Nov 3, 2008)
1305. Three year follow-up of a
multidisciplinary care and peer support model for the engagement of IDUs in
care and treatment for HCV infection.
1310. Efficacy Of Daily Dose
Consensus Interferon Alfacon-1(CIFN) And Ribavirin In Previous Non Responders
To Pegylated Interferon and Ribavirin In Patients With Advanced Fibrosis From
Chronic Hepatitis C. (updated
Nov 4, 2008)
LB6. Metformin with Peginterferon
Alfa-2a and Ribavirin in the Treatment of Naïve Genotype 1 Chronic Hepatitis C
Patients with Insulin Resistance (TRIC-1): Final Results of a Randomized and
265. Changes in Health-Related Quality of
Life are Associated with Disease Progression and Peginterferon Therapy in
Patients with Advanced Hepatitis C in the Hepatitis C Antiviral Long-Term
Treatment against Cirrhosis (HALT-C) Trial.
271. Reduction of Insulin Resistance with
Effective Clearance of Hepatitis C Infection: Results from the HALT-C
273. Reduced Hepatic Inflammation is
Related to HCV RNA Suppression and Correlates With Less Fibrosis Progression
and Fewer Cirrhosis Complications in the Hepatitis C Antiviral Long-Term
Treatment Against Cirrhosis (HALT-C) Trial.
512. Alfa-2a monotherapy could be a treatment option
for Chronic Hepatitis C in Patients Infected with HCV Genotype 2.
1227. High rates of sustained
virological response in HCV-infected injection drug users receiving directly observed
therapy with peginterferon alfa-2a and once daily ribavirin. (updated Nov 3, 2008)
1239. Are there differences in
treatment outcomes between HCV genotype 2 and 3 patients with advanced fibrosis
treated with peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin
1243. Effect of Time to Response on
Viral Breakthrough and Relapse Rates in Patients Infected With HCV Genotype 1
and Treated With Peginterferon Alfa-2a Plus Ribavirin.
1251. Very Low Viral Load (VLVL)
Relapse after Treatment for HCV: A unique group with
High Sustained Virologic Response (SVR) to low dose, Short Course Retreatment. (updated Nov 3, 2008)
1256. Higher Response Rate from
Peginterferon Alpha 2a Plus Ribavirin in Chronic
Hepatitis C Patients with Hemophilia.
1295. Sustained Virologic Response
Is Associated With Worse Qol During And Improved Qol After Treatment With
Peginterferon Alfa-2a And Ribavirin. (updated Nov 3, 2008)
High sustained virologic response rates in HCV genotype 1 relapser patients
retreated with peginterferon alfa-2a (40KD) plus ribavirin for 72 weeks.
Histologic Response to Peginterferon Alfa-2a Plus
Ribavirin in Treatment-Naive Latino and Non-Latino White Patients Infected With
HCV Genotype 1: The LATINO Study.
Pharmacokinetics (PK) of ribavirin (RBV) in patients with renal impairment or
end-stage renal disease (ESRD) and chronic hepatitis C (CHC) during treatment
with peginterferon alfa-2a (40KD) (PEGASYS®) and RBV (COPEGUS®).
A 72-week treatment duration with peginterferon alfa-2a (40KD) (PEGASYS®) plus
ribavirin (COPEGUS®) has a favorable risk:benefit
ratio in non-responders to pegylated interferon alfa-2b (12KD) plus ribavirin:
findings of the multinational REPEAT study.
1216. Impact of Advanced Fibrosis
and Cirrhosis on Sustained Virologic Response of HCV G1-Infected Patients:
Results of The Canadian POWeR Program.
1222. Impact of the use of drugs
and substitution treatments on the antiviral treatment of chronic hepatitis C
(HCV): analysis of compliance, virological response and quality of life
1224. Extended treatment with
peginterferon alfa-2b and ribavirin combination therapy can suppress the
relapse rate after treatment of chronic hepatitis C genotype 1 patients with
late viral response. (updated Nov 3, 2008)
1229. Virological Response to
Treatment with Pegylated Interferon alfa-2b and ribavirin chronic hepatitis C
in Children. (updated Nov 3, 2008)
1282. Effect of Interferon alfa-2b
plus ribavirin therapy on incidence of hepatocellular carcinoma in patients
with chronic hepatitis. (updated Nov 3, 2008)
Predictors of Treatment
268. Sustained Virologic Response (SVR) and
Predictors of Response in African American (AA) Patients in the IDEAL
(Individualized Dosing Efficacy Versus Flat Dosing to Assess OptimaL Pegylated
Interferon Therapy) Phase 3b Study.
270. Es-Citalopram for the prevention of
PEG-IFN-α and Ribavirin associated depression in HCV-infected patients
without psychiatric risk factors (CIPPAD-study).
1019. Hepatitis C Viral Genotype Age is a Predictor
of the Clinical Response to Interferon Therapy.
1249. Effect of obesity on
interferon stimulated genes expression in chronic HCV infection.
1259. Steatosis, Insulin
resistance, Iron overload, Fibrosis and Viral load as negative factors
affecting Early (EVR) and Sustained (SVR) Virological Response in patients with
Chronic Hepatitis C treated with peginterferon and ribavirin.
1260. Monitoring virologic on
treatment response to predict treatment outcome in patients with chronic
hepatitis C treated with pegylated interferon plus ribavirin: realtime PCR
assays and bDNA/TMA provide the same performances. (updated
Nov 3, 2008)
1270. Insulin-Resistance in Chronic
Hepatitis C patients: New Predictor of Sustained Virological Response
Independent of HCV Genotype and Liver Fibrosis Stage. (updated Nov 3, 2008)
1273. Asian Ethnicity is a
Significant Predictor of Sustained Virologic Response (SVR) to Combination
Therapy with Peginterferon (PEG IFN) and Ribavirin (RBV) in Chronic Hepatitis C
1301. Relationship between insulin
resistance (IR) and sustained virologic response (SVR) in the treatment of
Hepatitis C virus (HCV) with interferon and ribavirin. (updated Nov 4, 2008)
1334. Does steatosis influence the
effect of therapy and the progression of chronic liver disease caused by
1336. Insulin resistance, LDL
cholesterol and results of hepatitis C treatment.
1302. Treatment compliance in
patients taking RibaPak® or 200mg ribavirin: Preliminary analyses from the
1263. Prospective Analysis of
Depression During Antiviral Treatment for Hepatitis C:
Results of the VIRAHEP-C Study.
1284. Central Hypothyroidism in
patients with chronic hepatitis C.
1300. Autoimmune Thyroid Disease In
Chronic Hepatitis C Treated With Peg-IFN And Ribavirin: Prevalence, Incidence
And Influence On Therapeutic Outcome In 4498 Naive Patients.
1309. Importance of prior
psychiatric consultation in pegylated interferon and ribavirin combination
therapy for chronic hepatitis C.
Side Effect Management
209. Do growth factors
improve SVR in chronic HCV-genotype 1 patients treated with Peg-Interferon and
Substitute Opioid Therapy
1311. Pegylated Interferon Alfa-2a
(Peg-2a) Plus Ribavirin (RBV) For Patients With
Chronic Hepatitis C Virus (HCV) On Opioid Pharmacotherapy: Virological
Outcomes, Psychological Impact And Safety.
1335. Psychopathological Changes
and Quality of Life in HCV-Infected, Opioid-Dependent Patients During Maintenance therapy.